Chevallard R. Daniel's Insider Trades & SAST Disclosures
Chevallard R. Daniel's most recent trade in LENZ Therapeutics Inc. was a trade of 70,444 Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 9, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Chevallard R. Daniel.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| LENZ Therapeutics Inc. | Daniel R. Chevallard | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2025 | 70,444 | 70,444 | - | - | Stock Option (right to buy) | |
| LENZ Therapeutics Inc. | Daniel R. Chevallard | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 15.68 per share. | 14 May 2024 | 3,188 | 3,188 | - | 15.7 | 49,988 | Common Stock |
| LENZ Therapeutics Inc. | Daniel R. Chevallard | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2024 | 200,000 | 200,000 | - | - | Stock Option (right to buy) | |
| Viracta Therapeutics Inc | Daniel R. Chevallard | CFO and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2024 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Viracta Therapeutics Inc | Chevallard R. Daniel | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2024 | 6,889 | 105,711 | - | 0 | Common Stock | |
| Viracta Therapeutics Inc | R. Daniel Chevallard | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2024 | 6,889 | 34,444 | - | - | Restricted Stock Units | |
| Viracta Therapeutics Inc | R. Daniel Chevallard | CFO and COO | Sale of securities on an exchange or to another person at price $ 0.73 per share. | 25 Feb 2024 | 3,405 | 102,306 | - | 0.7 | 2,493 | Common Stock |
| Viracta Therapeutics Inc | Daniel R. Chevallard | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2023 | 6,888 | 99,165 | - | 0 | Common Stock | |
| Viracta Therapeutics Inc | Daniel R. Chevallard | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2023 | 6,888 | 48,222 | - | - | Restricted Stock Units | |
| Viracta Therapeutics Inc | Daniel R. Chevallard | CFO and COO | Sale of securities on an exchange or to another person at price $ 1.45 per share. | 25 Aug 2023 | 3,512 | 95,653 | - | 1.4 | 5,092 | Common Stock |
| Viracta Therapeutics Inc | Daniel R. Chevallard | CFO and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2023 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Viracta Therapeutics Inc | Daniel R. Chevallard | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2023 | 6,889 | 92,622 | - | 0 | Common Stock | |
| Viracta Therapeutics Inc | Daniel R. Chevallard | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2023 | 6,889 | 61,999 | - | - | Restricted Stock Units | |
| Viracta Therapeutics Inc | Daniel R. Chevallard | CFO and COO | Sale of securities on an exchange or to another person at price $ 1.68 per share. | 25 Feb 2023 | 3,599 | 89,023 | - | 1.7 | 6,051 | Common Stock |
| Viracta Therapeutics Inc | Daniel R. Chevallard | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2022 | 6,889 | 89,265 | - | 0 | Common Stock | |
| Viracta Therapeutics Inc | Daniel R. Chevallard | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2022 | 6,889 | 68,888 | - | - | Restricted Stock Units | |
| Viracta Therapeutics Inc | Daniel R. Chevallard | CFO and COO | Sale of securities on an exchange or to another person at price $ 2.72 per share. | 25 Nov 2022 | 3,532 | 85,733 | - | 2.7 | 9,606 | Common Stock |
| Viracta Therapeutics Inc | Daniel R. Chevallard | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2022 | 6,889 | 86,031 | - | 0 | Common Stock | |
| Viracta Therapeutics Inc | Daniel R. Chevallard | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2022 | 6,889 | 75,777 | - | - | Restricted Stock Units | |
| Viracta Therapeutics Inc | Daniel R. Chevallard | CFO and COO | Sale of securities on an exchange or to another person at price $ 4.02 per share. | 25 Aug 2022 | 3,655 | 82,376 | - | 4.0 | 14,679 | Common Stock |
| Viracta Therapeutics Inc | Daniel R. Chevallard | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2022 | 6,889 | 82,666 | - | - | Restricted Stock Units | |
| Viracta Therapeutics Inc | Daniel R. Chevallard | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2022 | 6,889 | 82,738 | - | 0 | Common Stock | |
| Viracta Therapeutics Inc | Daniel R. Chevallard | CFO and COO | Sale of securities on an exchange or to another person at price $ 1.90 per share. | 25 May 2022 | 3,596 | 79,142 | - | 1.9 | 6,836 | Common Stock |
| Viracta Therapeutics Inc | Daniel R. Chevallard | CFO and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2022 | 195,000 | 195,000 | - | - | Stock Option (Right to Buy) | |
| Viracta Therapeutics Inc | Daniel R. Chevallard | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2022 | 6,889 | 89,555 | - | - | Restricted Stock Units | |
| Viracta Therapeutics Inc | Daniel R. Chevallard | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2022 | 6,889 | 79,847 | - | 0 | Common Stock | |
| Viracta Therapeutics Inc | Daniel R. Chevallard | CFO and COO | Sale of securities on an exchange or to another person at price $ 2.78 per share. | 25 Feb 2022 | 3,998 | 75,849 | - | 2.8 | 11,112 | Common Stock |
| Viracta Therapeutics Inc | Daniel R. Chevallard | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2021 | 13,777 | 96,444 | - | - | Restricted Stock Units | |
| Viracta Therapeutics Inc | Daniel R. Chevallard | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2021 | 13,777 | 80,537 | - | 0 | Common Stock | |
| Viracta Therapeutics Inc | Daniel R. Chevallard | CFO and COO | Sale of securities on an exchange or to another person at price $ 4.82 per share. | 25 Nov 2021 | 4,325 | 72,958 | - | 4.8 | 20,843 | Common Stock |
| Viracta Therapeutics Inc | Daniel R. Chevallard | CFO and COO | Sale of securities on an exchange or to another person at price $ 4.80 per share. | 25 Nov 2021 | 3,254 | 77,283 | - | 4.8 | 15,621 | Common Stock |
| Viracta Therapeutics Inc | Daniel R. Chevallard | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.90 per share. | 28 Sep 2021 | 10,000 | 66,760 | - | 0.9 | 9,000 | Common Stock |
| Viracta Therapeutics Inc | Daniel R. Chevallard | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Sep 2021 | 10,000 | 88,817 | - | - | Stock Option (Right to Buy) | |
| Viracta Therapeutics Inc | Daniel R. Chevallard | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.90 per share. | 28 May 2021 | 12,000 | 56,760 | - | 0.9 | 10,800 | Common Stock |
| Viracta Therapeutics Inc | Daniel R. Chevallard | CFO and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2021 | 12,000 | 98,817 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges